Data investigation
One Trial on Fertility
A systematic review searched five databases for everything on weight-lowering drugs and natural female fertility. It found seven trials, six of them on orlistat, and exactly one on a GLP-1.
People are taking these drugs hoping to conceive, and unplanned pregnancies on them are discussed everywhere. A systematic review searched five databases for everything published on weight-lowering drugs and natural female fertility, screened 2,731 records, and found seven trials — six of which studied orlistat.[1] Exactly one assessed a GLP-1.
What the search returned
Seven clinical trials, six of them randomized, covering 575 women in total. Individual studies enrolled between 40 and 120 participants, aged on average between 25.9 and 29.7. The outcomes sought were ovulation, conception, pregnancy and live birth.
| Comparison | Finding |
|---|---|
| Orlistat vs lifestyle modification (4 trials) | Higher ovulation rate with orlistat |
| Orlistat vs metformin, ovulation (meta-analysis) | No significant difference — RR 0.78 (95% CI 0.41–1.49), p = 0.45 |
| Orlistat vs lifestyle, pregnancy (1 trial) | 23.3% vs 6.7%, p = 0.044 |
| Semaglutide + metformin vs metformin (1 trial) | Pregnancy 35% vs 15%, p < 0.05 |
| Live births | Not adequately assessed by any of them |
Orlistat is a drug that blocks fat absorption in the gut. It is barely prescribed now, and it is what six-sevenths of this literature is about. That is the practical meaning of the review: the evidence on weight-lowering drugs and fertility was mostly assembled before the drugs people now take existed.
The one GLP-1 result
A single trial found that adding semaglutide to metformin raised the pregnancy rate from 15% to 35%. Doubling a conception rate sounds like a large finding, and in a study of this size it is a small number of pregnancies.
And the outcome is pregnancy, not a baby. The review says plainly that future studies need to evaluate live birth rates in adequately powered studies, which is an acknowledgment that the outcome people actually want has not been measured.
Nobody has published whether these drugs help anyone have a baby.
The tension nobody resolves
It also matters that fertility can return before anyone plans for it. Weight loss restores ovulation in people who were not ovulating, which is the mechanism most of this literature is built on — and it means conception can happen while someone still assumes it cannot. The label intervals, what 36 studies say about exposure around conception, and the first measurement of whether semaglutide reaches breast milk are all in pregnancy and trying to conceive.
For the specific case of polycystic ovary syndrome, where the fertility question has its own literature, see GLP-1s for PCOS.
What can honestly be said
- Weight loss improves fertility in people whose fertility is impaired by weight. That is long established and is not in question.
- Whether these particular drugs do it better than other routes to the same weight loss is unstudied. One trial is not an evidence base.
- Nobody has measured live births. Pregnancy rate is a step short of the outcome.
- Contraception matters more than people expect while taking these drugs, precisely because fertility can return unannounced.
None of which is a reason to avoid treatment. It is a reason to stop treating a widely repeated story as though it rested on evidence, and to have the conversation with a clinician before rather than after.
Frequently Asked Questions
References
- 1.Alnaimi SJ, Alsugeir DM, Wei L, et al. Weight-Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta-Analysis Clinical Obesity. 2026. PMID: 42307450.
Related research
A Benefit Nobody Observed
A cardiology journal reports GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease. Nobody in the study took the drug.
6 min read
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
7 min read
Another Molecule You Cannot Buy
A dual agonist reported 14.7% weight loss in thirteen weeks. The drug is approved nowhere, and a thirteen-week figure sits on the steepest part of a curve that flattens.
6 min read
Comparing Trials That Never Met
We refused a cross-trial comparison in an earlier article. Here is the methodologically proper version of what we refused — and why it appears to contradict a head-to-head trial without actually doing so.
7 min read
How to Trust an Observational Study
We have twice warned that a very large hazard ratio from an observational study is telling you about the study. Here is one reporting 0.42 and 0.58 that deserves trust — and the specific techniques that earn it.
7 min read